Intravenous Zoledronate 4 mg for the treatment of post-menopausal osteoporosis: A prospective open-labeled study
Background: Zoledronate 5 mg intravenous (IV) annually is approved for treatment of post-menopausal osteoporosis. Zoledronate 4 mg which is approved for the treatment of cancer related hypercalcemia can be an alternative for Asian women who have smaller stature. Objectives: To examine the efficacy a...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Elsevier
2022-06-01
|
| Colección: | Bone Reports |
| Materias: | |
| Acceso en línea: | http://www.sciencedirect.com/science/article/pii/S2352187221004101 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|